Alto Neuroscience, Inc. (ANRO) Upgraded to Buy: Here's What You Should Know
Wall Street Analysts Predict a 29.38% Upside in Alto Neuroscience, Inc. (ANRO): Here's What You Should Know
BTIG Reiterates Buy on Alto Neuroscience, Maintains $37 Price Target
Alto Neuroscience Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Alto Neuroscience (ANRO) Stock Looks Fully Priced On Book Value
Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
HC Wainwright & Co. Maintains Buy on Alto Neuroscience, Raises Price Target to $60
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
Alto Neuroscience Promotes Nick Smith To President, CFO, Effective Aug. 26
HC Wainwright & Co. Maintains Buy on Alto Neuroscience, Raises Price Target to $55
Alto Neuroscience (ANRO) Reports Another Quarterly Loss, Is The Stock Already Overvalued?
Are Alto Neuroscience’s (ANRO) Rising Losses Funding a Stronger Depression Pipeline or Diluting Discipline?
Alto Neuroscience (ANRO) Stock Looks Stretched On Expanded ALTO 207 Plans
Wedbush Maintains Neutral on Alto Neuroscience, Raises Price Target to $26
BTIG Maintains Buy on Alto Neuroscience, Raises Price Target to $37
Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Alto Neuroscience Q2 EPS $(0.65) Beats $(0.73) Estimate
Alto Neuroscience: Buy ALTO-207 Advancement TRD And Other Expansion Indications
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.